Retatrutide vs tirzepatide: triple agonist versus a proven dual agonist

What is the difference between retatrutide and tirzepatide?

Both molecules come from the same lab and the same idea: mimic the gut hormones that govern appetite and blood sugar, then re-engineer them to last a week. The difference is how many hormone receptors each one switches on. Tirzepatide is a dual agonist — it activates the GLP-1 and GIP receptors. Retatrutide adds a third target, the glucagon receptor, which makes it a triple agonist. Both are once-weekly subcutaneous injections, both were designed by Eli Lilly, and both drive large amounts of weight loss in trials.

The gap that matters most, though, is not chemistry — it is status. Tirzepatide is an approved drug you can be prescribed today, sold as Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea. Retatrutide is still investigational. Its published evidence stops at Phase 2, its Phase 3 program is ongoing, and it is not approved by any regulator on earth. So a "retatrutide vs tirzepatide" comparison is really two comparisons stacked together: a mechanism comparison (three receptors versus two) and an evidence comparison (early trials versus a mature, approved drug). Keeping those two threads separate is the whole trick to reading the numbers honestly.

Triple agonist vs dual agonist: what the glucagon receptor adds

GLP-1 and GIP are incretins — hormones the gut releases after eating that boost glucose-dependent insulin secretion, slow the stomach, and signal fullness. GLP-1 physiology has been mapped in detail for decades (PubMed 17928588), and the broader role of these peptide hormones in appetite and metabolism is well reviewed (PubMed 34067710). Tirzepatide combines both incretin receptors; that dual action is why it outperformed single-receptor semaglutide in a head-to-head obesity trial (PubMed 40353578).

Retatrutide keeps both incretin levers and pulls a third: glucagon. On its own, glucagon raises blood sugar, which sounds like the opposite of what a metabolic drug should do. But glucagon also increases energy expenditure and pushes the liver to burn fat. The bet behind a triple agonist is that the GLP-1 and GIP components blunt glucagon's glucose-raising effect while its metabolic-rate and liver-fat benefits add to the weight loss. Phase 2 data are consistent with that idea: retatrutide produced steep weight loss and, in a liver-fat substudy, cut hepatic fat dramatically, with most participants on the higher doses reaching normal liver-fat levels (PubMed 38858523).

Mechanistically, it is plausible that three levers beat two. But "more receptors" has never guaranteed "better outcome" for any given person or endpoint — which is exactly why an approved drug's Phase 3 record still carries more weight than a newcomer's mechanism story. For the wider family, see how GLP-1 receptor agonists work.

Retatrutide vs tirzepatide for weight loss: the numbers everyone quotes

Here are the figures that drive the whole conversation. In its Phase 2 obesity trial — 338 adults with obesity, published in 2023 — retatrutide produced a least-squares mean weight reduction of about 24.2% at 48 weeks in the highest-dose (12 mg) group, versus roughly 2% on placebo (PubMed 37366315). In a separate Phase 2 trial in people with type 2 diabetes, it lowered HbA1c by up to about two percentage points and cut weight by up to roughly 17% at 36 weeks (PubMed 37385280).

Tirzepatide's headline comes from a much larger Phase 3 trial, SURMOUNT-1: 2,539 adults, 72 weeks, and a mean weight reduction of 20.9% at the 15 mg dose (PubMed 35658024). In people who also had type 2 diabetes, SURMOUNT-2 showed 12.8% to 14.7% (PubMed 37385275).

Put side by side, 24.2% looks like it beats 20.9%, and Lilly's more recent Phase 3 topline for retatrutide — announced publicly but not yet peer-reviewed — put weight loss near 28% at higher doses over 68 to 80 weeks, bigger still. That is where most "retatrutide is stronger" claims originate. The numbers themselves are real. The comparison, however, is not clean, and the next section explains exactly why.

Why the cross-trial comparison is unreliable

Comparing retatrutide's 24% to tirzepatide's 21% means comparing two different experiments, not two drugs run under the same conditions. Four things break the comparison:

• Different trial phase and size. Retatrutide's number is Phase 2 in 338 people; tirzepatide's is Phase 3 in 2,539. Small early-stage trials often report larger effects that shrink when a drug is tested at scale.
• Different duration. Retatrutide's 24% was measured at 48 weeks; tirzepatide's 21% at 72 weeks. Retatrutide's weight curve had not clearly plateaued at 48 weeks, so the two endpoints are not even the same finish line.
• Different populations and sites. Entry criteria, baseline weight, and background care differ between trials, and even small differences can shift the headline percentage.
• No head-to-head trial exists. Nobody has randomized the same group of people to retatrutide or tirzepatide and measured them the same way.

Reviews of this drug class make the same warning: indirect, cross-trial comparisons are unreliable, and only randomized head-to-head studies settle which agent does more (PubMed 33767808). The tirzepatide-versus-semaglutide story is the cautionary example: for years people leaned on cross-trial math, then the SURMOUNT-5 head-to-head trial finally measured both drugs together and produced a cleaner answer (see that comparison here). Until a retatrutide-versus-tirzepatide trial is actually run, the honest verdict is that retatrutide's numbers are very promising and not yet comparable.

The numbers side by side

The table lines up the two molecules across the dimensions people weigh when comparing them. It is a summary of published and announced trial data, not a recommendation, and the weight-loss figures come from separate trials rather than a head-to-head study.

Retatrutide vs tirzepatide side effects

Both drugs share a side-effect signature because they act on the same gut machinery. Nausea, diarrhea, vomiting, and constipation top the list, are mostly mild to moderate, and cluster around dose increases. In retatrutide's Phase 2 obesity trial, these gastrointestinal events were the most common adverse effects and rose with dose (PubMed 37366315). Tirzepatide's trials show the same pattern, and its published safety data span far larger numbers of patients.

Retatrutide has one notable extra signal. In Phase 2, it produced dose-dependent increases in heart rate that peaked around 24 weeks and then eased, and — consistent with its glucagon activity — small, mostly transient rises in blood glucose could appear early before the incretin components took over. Whether these matter clinically at scale is precisely one of the questions its Phase 3 program is powered to answer.

On the numbers reported so far, retatrutide's higher doses tend to carry higher gastrointestinal rates than tirzepatide's — which is what you would expect from a more aggressive, three-receptor drug, but again, without a head-to-head trial the tolerability comparison stays indirect. Both classes also carry the cautions that apply to approved incretin drugs: gallbladder problems, a pancreatitis signal, and a rodent thyroid-tumor warning. A licensed clinician weighs those against the potential benefit for each individual, and much of a drug's real safety picture only emerges once large Phase 3 populations are studied.

Is retatrutide FDA approved? The approval-status gap

This is the single most important practical difference between the two, and it is easy to lose behind the weight-loss percentages. Tirzepatide is fully approved: the FDA cleared it as Mounjaro for type 2 diabetes in 2022 and Zepbound for obesity in 2023, with a later approval for obstructive sleep apnea. It is prescription-only, made to pharmaceutical quality standards, and covered — patchily — by insurance.

Retatrutide is none of those things yet. It is investigational, which means it is legally available only to people enrolled in Eli Lilly's clinical trials. It cannot be legally prescribed, sold, or compounded as a medicine anywhere. The vials advertised online as "retatrutide" for "research use only" or "not for human consumption" are not the trial drug, are not made under pharmaceutical controls, and independent testing of similar gray-market peptides has repeatedly found inconsistent identity and purity. Injecting them is a different risk category from taking an approved medicine — you cannot verify the dose, the purity, or even the contents. Where the legal lines actually sit is covered in our guide to whether peptides are legal. PepMate does not sell peptides, link to sources, or recommend any product.

When will retatrutide be available?

Retatrutide is in its Phase 3 program, known as TRIUMPH. Lilly has reported topline results from several of these trials — including large weight-loss figures near 28% at the highest doses over 68 to 80 weeks — but those are press-release toplines, not the peer-reviewed, fully published datasets that regulators and clinicians scrutinize. That distinction matters: the Phase 2 papers cited on this page have been through peer review; the Phase 3 numbers, so far, have not.

On timing, Lilly has signaled that it intends to file for approval, with a regulatory submission expected around late 2026 and an FDA review that typically runs several months to about a year after filing. Realistic estimates put a possible approval somewhere in the 2027-2028 window, with any commercial launch after that — and drug timelines routinely slip. Nothing here is a promise of approval: compounds can still fail or be delayed in Phase 3. For now, tirzepatide is the drug that exists on pharmacy shelves, and retatrutide is the one to watch. For the broader field, see our overview of peptides studied for weight loss.

So which is better, retatrutide or tirzepatide?

It depends entirely on what "better" means to you. If it means the largest weight loss reported in a trial, retatrutide's numbers currently lead — but on Phase 2 and not-yet-published Phase 3 data, without a head-to-head test. If it means a drug you can actually be prescribed, backed by a mature evidence base across multiple large Phase 3 trials and a proven head-to-head win over semaglutide, tirzepatide is the only real answer today. Those are not the same question, and conflating them is how people end up chasing unregulated vials on the strength of a single percentage.

The disciplined read: retatrutide is one of the most promising obesity drugs in development, and its triple-agonist mechanism is a genuinely new lever. Tirzepatide is a known quantity with regulatory approval, quality control, and years of data behind it. When retatrutide's Phase 3 results are fully published — and, eventually, if a direct comparison trial is ever run — the picture will sharpen. Until then, the choice that exists in the real world is between an approved drug and enrollment in a trial, which is a conversation for a licensed clinician rather than a spec-sheet decision.

Whatever a clinician chooses, both drugs behave like long-term treatments rather than a short course: stopping tends to reverse the gains, as semaglutide's withdrawal data showed when participants regained about two-thirds of their lost weight within a year (PubMed 35441470). That is a strong argument for tracking what actually happens week to week. Background on how these incretin drugs are engineered is summarized in PubMed 31050435.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — PubMed 37366315
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — PubMed 37385280
3. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — PubMed 38858523
4. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — PubMed 35658024
5. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — PubMed 37385275
6. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed 40353578
7. GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
8. The physiology of glucagon-like peptide 1 — PubMed 17928588
9. The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
10. Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
11. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435

Keep reading